Amundi Asset Management US’s Alder Biopharmaceuticals ALDR Stock Holding History

Amundi Asset Management US’s Portfolio ALDR Stock Details ALDR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-123,900	Closed	-$1.96M	–	1672
2018 Q2	$1.96M	Buy	+123,900	New	+$1.88M	﹤0.01%	1123
2017 Q3	–	Sell	-467,813	Closed	-$5.36M	–	533
2017 Q2	$5.36M	Sell	467,813 -316,076	-40%	-$5.84M	0.02%	393
2017 Q1	$16.3M	Sell	783,889 -20,996	-3%	-$465K	0.05%	230
2016 Q4	$16.7M	Sell	804,885 -130,556	-14%	-$3.39M	0.06%	234
2016 Q3	$30.7M	Buy	935,441 +110,453	+13%	+$3.36M	0.11%	157
2016 Q2	$20.6M	Buy	824,988 +402,270	+95%	+$10.9M	0.07%	205
2016 Q1	$10.4M	Sell	422,718 -154,296	-27%	-$3.57M	0.04%	288
2015 Q4	$19.1M	Sell	577,014 -405,093	-41%	-$13.7M	0.07%	227
2015 Q3	$32.2M	Buy	982,107 +47,330	+5%	+$2.01M	0.13%	159
2015 Q2	$49.5M	Buy	+934,777	New	+$34M	0.18%	148

Other funds holding ALDR

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCMI

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Amundi Asset Management US's ALDR Position: Q3 2018 in Review

Amundi Asset Management US sold out of Alder Biopharmaceuticals (ALDR) in Q3 2018, closing a stake of 123,900 shares — an estimated $1.96M sold.

Amundi Asset Management US first reported a position in ALDR in Q2 2015 and held it in 10 quarters. The position peaked at $49.5M in Q2 2015. 128 funds tracked by Wall St. Rank hold ALDR as of Q3 2018.

Amundi Asset Management US reported no remaining Alder Biopharmaceuticals position as of Q3 2018 after selling out during the quarter.
Amundi Asset Management US sold 123,900 Alder Biopharmaceuticals shares in Q3 2018, an estimated $1.96M.
Amundi Asset Management US first reported a position in Alder Biopharmaceuticals in Q2 2015 and held it in 10 quarters.
Amundi Asset Management US's Alder Biopharmaceuticals position peaked at $49.5M in Q2 2015.
128 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q3 2018.

Based on Amundi Asset Management US's 13F filing for Q3 2018, filed 14 Nov 2018.